Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Nine-Person Gencia Inks $500 Million Collaboration Deal with Takeda

Takeda Pharmaceutical Company, headquartered in Osaka, Japan, and Charlottesville, Va.-based Gencia LLC announced today a $500 million partnership deal. The two companies plan to work on a new class of small molecules as possible drugs for hematological and inflammatory diseases. The focus of the collaboration will be on Mitochondrial Agonists of the Glucocorticoid Receptor (MAGR), […]

Read More »

Agilent Acquires Seahorse Bioscience and its XF Technology for $235 Million

SANTA CLARA, Calif.—Pharma diagnostics company Agilent Technologies, Inc. (A) inked a $235 million deal to acquire privately-held Seahorse Bioscience to complement its mass spectrometry solutions and expand pharma offerings, the company announced this morning. Agilent said Seahorse’s technology enables researchers to “better understand cell health, function and signaling, and how the cell may be impacted […]

Read More »

Gilead Borrows $10 Billion, Spurring Acquisition Speculation

Foster City, Calif.-based Gilead Sciences, Inc. (GILD) announced Wednesday that it filed to borrow $10 billion in an underwritten, registered public offering. The offering will have six tranches that mature between 2018 and 2046.   The offering is planned to close Sept. 14, 2015 and are rated A- by Standard & Poor’s and A3 by […]

Read More »

Biogen Forges $544M Deal to Take on Celgene With a Rival Autoimmune Drug

Biogen, Inc., headquartered in Cambridge, Mass., announced today that it licensed MT-1303 from Mitsubishi Tanabe Pharma Corporation, located in Osaka, Japan. MT-1303 is being investigated in a number of autoimmune disorders, including multiple sclerosis (MS), ulcerative colitis, Crohn’s disease and others.   Biogen will obtain worldwide rights to MT-1303, excluding Asia. It will oversee global […]

Read More »

Celsion Updates Clinical Trial Data and Slashes 20% of Workforce

Lawrenceville, N.J.-based Celsion Corporation (CLSN) announced today that it completed the integration of its June 2014 acquisition of EGEN, Inc., and as part of the consolidation, had cut 15 to 20 percent of its staff and annual operational costs.   In June 2014, Celsion, which focuses on cancer drug development, acquired Huntsville, Ala.-based EGEN, Inc., […]

Read More »

GlaxoSmithKline lung drug fails to extend life in huge study

GlaxoSmithKline’s inhaled medicine Breo failed to prolong life in patients with chronic respiratory disease in a high-stakes clinical trial of 16,500 people, torpedoing hopes of a sales boost for the drug. Shares in Britain’s biggest drugmaker fell 1.5 percent on Wednesday, lagging a strong London market, in reaction to the news announced by the company […]

Read More »

Pacira sues FDA over pain drug marketing restrictions

Pacira Pharmaceuticals Inc on Tuesday filed a lawsuit seeking a court order allowing it to promote its post-surgery pain drug, Exparel, for a wide range of surgeries, which the U.S. Food and Drug Administration opposes. The lawsuit, filed in federal court in Manhattan, cites another New York judge’s recent decision allowing Irish drugmaker Amarin Plc […]

Read More »

Concordia Healthcare Snaps Up Rare Disease Drugmaker in $3.5 Billion Deal

Canadian company Concordia Healthcare[2] (CXR.TO[3]), headquartered in Oakville, Ontario, announced[4] today that it is buying Amdipharm Mercury Limited[5] (AMCo) from Cinven[6] for $3.5 billion. Cinven is a European private equity firm. The deal will be a combination of cash, common shares of Concordia, and a performance-based earn-out payable in cash. “This acquisition is a key […]

Read More »

AstraZeneca PLC And Starpharma Ink Drug Delivery Deal Worth up to $450 Million

MELBOURNE, Australia— AstraZeneca PLC[2] (AZN[3]) struck a deal worth up to $450 million with Australia-based Starpharma[4] to license that company’s DEP drug delivery platform for use with its oncology medications. Starpharma’s licensing agreement with AstraZeneca focuses on novel compounds, and not on unmodified drugs in currently marketed formulations. AstraZeneca did not disclose which oncology drug […]

Read More »

Cosmo gets U.S. approval for agent aimed at easing polyp removal

Cosmo Pharmaceuticals SA said on Friday that the U.S. Food and Drug Administration has given marketing authorization for SIC 8000, a product used in gastrointestinal tract procedures. Cosmo said SIC 8000 lifts mucous membranes in the esophagus, stomach, small and large intestines and other organs during removal of things such as polyps. Its shares, which […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom